- Bio-Techne Corporation has opened a 10,000-square-foot GMP small molecule manufacturing facility in Bristol, United Kingdom, to support cell therapy developers.
- The facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms and is fully operational, manufacturing GMP-grade small molecules for cell therapy development.
Bio-Techne Corporation has opened a new Good Manufacturing Practice (GMP) small molecule manufacturing facility in Bristol, United Kingdom, expanding its capacity to supply materials for cell therapy development and commercialization. The purpose-built 10,000-square-foot facility is designed to support scalable and reproducible manufacturing processes and is already producing GMP-grade small molecules for customers developing cell therapies worldwide.
The facility includes five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Bio-Techne said the site strengthens its ability to supply GMP materials supported by quality systems and global supply capabilities.
The Bristol facility forms part of Bio-Techne’s broader manufacturing network, which includes recombinant protein manufacturing operations in Minneapolis, Minnesota, GMP capabilities in St. Paul, and a strategic relationship with Wilson Wolf Corporation, a manufacturer of cell culture devices, including the G-Rex platform. The company’s portfolio includes GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support.
“As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale. The Bristol investment is intended to provide therapy developers with GMP materials, manufacturing expertise, and supply chain reliability to support development and commercialization.”
Kim Kelderman, president and chief executive officer of Bio-Techne
Bio-Techne said the facility addresses cell therapy developers’ needs to reduce manufacturing variability, standardize processes, and scale production while meeting regulatory expectations. The company expects its expanded manufacturing capabilities to support customers from research and clinical development through commercial production.
